Wall Street analysts expect Eli Lilly and Co (NYSE:LLY) to report sales of $5.52 billion for the current quarter, Zacks reports. Four analysts have provided estimates for Eli Lilly and’s earnings, with the lowest sales estimate coming in at $5.45 billion and the highest estimate coming in at $5.63 billion. Eli Lilly and reported sales of $5.23 billion in the same quarter last year, which indicates a positive year over year growth rate of 5.5%. The company is expected to report its next quarterly earnings report before the market opens on Tuesday, April 24th.
On average, analysts expect that Eli Lilly and will report full-year sales of $23.43 billion for the current year, with estimates ranging from $23.15 billion to $23.67 billion. For the next financial year, analysts expect that the business will post sales of $23.83 billion per share, with estimates ranging from $23.31 billion to $24.17 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Eli Lilly and.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The firm had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $5.93 billion. During the same quarter in the prior year, the business posted $0.95 earnings per share. The business’s quarterly revenue was up 7.0% on a year-over-year basis.
A number of equities research analysts recently issued reports on LLY shares. Jefferies Group set a $90.00 price objective on Eli Lilly and and gave the stock a “buy” rating in a research report on Friday, April 13th. Credit Suisse Group set a $80.00 price objective on Eli Lilly and and gave the stock a “hold” rating in a research report on Sunday. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a research report on Monday, March 26th. JPMorgan Chase set a $105.00 price objective on Eli Lilly and and gave the stock a “buy” rating in a research report on Monday, February 26th. Finally, Bank of America lowered their price objective on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a research report on Thursday, February 1st. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. Eli Lilly and presently has an average rating of “Buy” and a consensus target price of $93.16.
Shares of LLY stock traded up $1.14 on Monday, reaching $80.20. The company’s stock had a trading volume of 4,015,861 shares, compared to its average volume of 4,711,505. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.01 and a current ratio of 1.32. Eli Lilly and has a 12-month low of $73.69 and a 12-month high of $89.09. The company has a market capitalization of $86,617.97, a PE ratio of 18.74, a price-to-earnings-growth ratio of 1.44 and a beta of 0.26.
In other news, SVP Susan Mahony sold 22,544 shares of the firm’s stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $80.09, for a total transaction of $1,805,548.96. Following the transaction, the senior vice president now directly owns 45,652 shares of the company’s stock, valued at $3,656,268.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jeffrey N. Simmons sold 9,625 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.12, for a total value of $780,780.00. Following the transaction, the senior vice president now directly owns 152,120 shares in the company, valued at $12,339,974.40. The disclosure for this sale can be found here. Insiders have sold 42,970 shares of company stock worth $3,444,557 in the last 90 days. Company insiders own 0.11% of the company’s stock.
Several large investors have recently made changes to their positions in the company. BlackRock Inc. grew its stake in shares of Eli Lilly and by 1.2% in the fourth quarter. BlackRock Inc. now owns 63,854,112 shares of the company’s stock worth $5,393,119,000 after purchasing an additional 776,893 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Eli Lilly and by 2.7% in the fourth quarter. Franklin Resources Inc. now owns 28,519,524 shares of the company’s stock worth $2,408,787,000 after purchasing an additional 754,681 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Eli Lilly and by 16.1% in the third quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock worth $928,719,000 after purchasing an additional 1,503,918 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Eli Lilly and by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 9,854,964 shares of the company’s stock worth $830,522,000 after purchasing an additional 406,812 shares during the last quarter. Finally, UBS Asset Management Americas Inc. grew its stake in shares of Eli Lilly and by 1.8% in the fourth quarter. UBS Asset Management Americas Inc. now owns 6,636,386 shares of the company’s stock worth $560,509,000 after purchasing an additional 115,499 shares during the last quarter. 77.69% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This report was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.thelincolnianonline.com/2018/04/24/brokerages-anticipate-eli-lilly-and-co-lly-will-post-quarterly-sales-of-5-52-billion.html.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.